Dermatologic Adverse Events Associated with T-Cell Engager Therapy - PubMed
3 hours ago
- #oncology
- #T-cell engager therapy
- #dermatologic adverse events
- T-cell engager therapies, such as bispecific T-cell engagers and tebentafusp, are a growing class of anticancer immunotherapies with distinct dermatologic adverse events (AEs).
- Tebentafusp causes diffuse erythematous, often photodistributed eruptions in most patients, while talquetamab leads to cutaneous, nail, and oral toxicities due to GPRC5D expression in keratinized tissues.
- Subcutaneous CD20- and BCMA-targeted agents frequently cause low-grade, self-limited injection-site reactions, and blinatumomab/CD19-/CD20-directed agents are associated with heterogeneous rashes.
- Most dermatologic AEs can be managed with topical corticosteroids, emollients, antihistamines, or brief systemic corticosteroids without discontinuing treatment.
- Recognizing agent-specific, mechanistically linked patterns is crucial as T-cell engager therapies become more integrated into oncology practice.